Channel Title: Radcliffe Cardiology Channel Description: We put great communication at the heart of better healthcare. Radcliffe equips healthcare professionals with the skills and practical insights they need to do their best for patients, by bringing the world’s cardiovascular, renal and metabolic (CVRM) knowledge to life. We combine scientific rigour with communications expertise and technical mastery, to make knowledge-sharing as effortless and effective as possible. We believe great communication is at the heart of great healthcare. Powerful research and ingenious innovation have always fuelled progress in health but it’s the way that new ideas are shared that ensures positive change happens quickly and equitably. For us, this is always a blend of the medium and the message – where, when and how important knowledge is communicated. Content intended for healthcare professionals only. <video> AHA 24: OPTION: LAA Closure with Oral Anticoagulation after AF Ablation Description: Safety and efficacy outcomes comparing left atrial appendage (LAA) closure with the WATCHMAN FLX device to oral anticoagulation (OAC) following atrial fibrillation (AF) catheter ablation. Dr Oussama Wazni (The Cleveland Clinic Foundation, Ohio, US) joins us onsite at AHA Conference to discuss the findings from OPTION (NCT03795298). OPTION is a prospective, multi-center, multi-national trial where patients with moderate to high risk of stroke who received AF catheter ablation were randomized to receive either LAA with the WATCHMAN FLX device or market-approved OAC. 1,600 patients were enrolled and were followed up through 36 months. The primary effectiveness endpoint is stroke, all cause death, systemic embolism, and the primary safety endpoint is non-procedural bleeding. Interview Questions: 1. What is the reasoning behind the OPTION trial? 2. What is the current research landscape for LAA closure following AF ablation? 3. What was the study design and patient population? 4. What were the key findings? 5. What are the take-home messages for practice? 6. What further research is needed in this area, and what are the next steps? Recorded remotely from Ohio, 2024. Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook: https://www.facebook.com/RadcliffeCardiology Follow us on X: https://x.com/radcliffeCARDIO </video> <video> Clinical Evidence and Implementation of SCD Risk Management Description: During NVVC 2024 in Papendal (NL) Prof Christian Meyer (UK Düsseldorf, DE) outlines a five-step approach for considering wearable defibrillators (WCDs), focusing on ejection fraction as a critical factor, particularly below 35% in ischemic cardiomyopathy. For non-ischemic cardiomyopathy, late enhancement patterns and details are key. This aligns with the 2022 ESC guidelines, emphasising MRI data and genetics, though genetic test results often take weeks to months. WCDs provide an opportunity to manage high-risk patients during this waiting period. Additional factors like syncope and non-sustained VT are also valuable for risk stratification. To view the complete symposium, please click here: https://www.radcliffecardiology.com/video-index/clinical-evidence-and-implementation-scd-risk-management This video is sponsored by Zoll. This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook: https://www.facebook.com/RadcliffeCardiology Follow us on X: https://x.com/radcliffeCARDIO </video> <video> Leadless Pacemakers in Patients with Chronic Kidney Disease Description: In the latest episode of Arrhythmia Academy's Journal Club, Dr David Duncker (Hannover Heart Rhythm Center, DE) is joined by Dr Gianfranco Mitacchione (University Of Brescia, IT) to discuss leadless pacemakers in patients with chronic kidney disease. Dr Mitacchione provides the current guideline recommendations for leadless pacemakers and presents data from the i-LEAPER (NCT05528029) multi-center study, investigating the safety and efficacy outcomes of leadless pacemaker implantation in patients with different stages of chronic kidney disease. Dr Duncker and Dr Mitacchione then dive deeper into the outcomes of i-LEAPER, focusing on how the complication rates and follow ups differed for each patient group. Recorded remotely from Hannover and Brescia, 2024. Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook: https://www.facebook.com/RadcliffeCardiology Follow us on X: https://x.com/radcliffeCARDIO </video> <video> Insights in Cardiovascular Innovation and Research: A Conversation with Dr Michael Gibson Description: In this episode of the "Innovations in Cardiology" series, host Dr. Dipti Itchhaporia, former president of the ACC, is joined by Dr. C. Michael Gibson, CEO of the Baim Institute for Research, for an insightful discussion on the latest advancements and future directions in cardiovascular innovation for 2024. Dr. Itchhaporia and Dr. Gibson explore strategies to enhance efficiency in cardiovascular research, with a focus on direct-to-patient trials. They delve into how this approach can be optimized to better target patients and improve outcomes. Dr. Gibson shares details about a groundbreaking platform being developed to support long-term follow-up studies, enabling patient monitoring for up to 20 years through persistent follow-up alerts. The conversation also touches on key findings from the Apple Heart Study, particularly in relation to atrial fibrillation detection via the Apple Watch, and the differences in compliance rates between older and younger patients. Additionally, they discuss the upcoming results of the Heartline Study, which focuses on patients aged 65 and older. Looking ahead, Dr. Itchhaporia and Dr. Gibson reflect on the future of cardiovascular care, including the potential for personalized care plans tailored to each patient. They consider the timeline for integrating this approach into clinical practice, potential barriers to implementation, and the significant opportunities it presents for improving patient outcomes. If you have any questions or suggestions for topics to cover on the Radcliffe Podcast, please email managingeditor@ecrjournal.com. Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook: https://www.facebook.com/RadcliffeCardiology Follow us on X: https://x.com/radcliffeCARDIO </video> <video> Parallax | Ep 123: Redefining Cardiology Careers: Flexibility, Equity and Advancement Description: In this compelling episode of Parallax, host Ankur Kalra sits down with Dr Sharonne Hayes, a trailblazing Professor of Cardiovascular Medicine and the vice chair for academic advancement and faculty development at Mayo Clinic. Together, they explore the critical intersections of career flexibility, diversity, and inclusion in modern medicine. Drawing from her extensive experience, Dr Hayes challenges traditional career paradigms in cardiology, offering a nuanced perspective on professional growth that prioritizes personal well-being and systemic change. The conversation delves deep into the complex landscape of medical careers, addressing unconscious biases, workforce equity, and the transformative power of inclusive leadership. Listeners will gain profound insights into strategic career navigation, practical strategies for achieving academic recognition, and the critical importance of health equity in cardiovascular care. Throughout the episode, Dr Hayes provides a masterclass in professional development, sharing her unique approach to career management that balances personal priorities with professional aspirations. From founding the Women's Heart Clinic to her groundbreaking research on academic rankings, she offers a roadmap for cardiologists seeking meaningful and flexible career paths. A must-listen for medical professionals, educators, and anyone passionate about creating more equitable and supportive healthcare environments. Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook: https://www.facebook.com/RadcliffeCardiology Follow us on X: https://x.com/radcliffeCARDIO </video> <video> Parallax | Ep 125: Structural Interventions and Emerging Pharmacotherapies: The Year 2024 In Review Description: In this week's Parallax, Dr Ankur Kalra welcomes back Dr Sukhjinder Nijjer for their much-anticipated annual review of advancements in cardiovascular medicine that defined the year 2024. Dr Nijjer, a Consultant Cardiologist in the UK, serves as the President of the Royal Society of Medicine and is an Honorary Senior Clinical Lecturer at Imperial College London. This episode explores emerging trends in the treatment of valvular heart disease, focussing on TAVI procedures and transcatheter interventions. It also covers recent advancements in pharmacological management for cardiovascular conditions. Drs Kalra and Nijjer share their perspectives and experiences, offering valuable insights, practical tips and considerations when interpreting this year’s most impactful trials: EARLY TAVR RESHAPE 2 MATTERHORN TRILUMINATE TOPSPIN FINEARTS-HF What are the most impactful cardiovascular trials of 2024? How do Dr Kalra and Dr Nijjer integrate the latest information into their daily practices? Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook: https://www.facebook.com/RadcliffeCardiology Follow us on X: https://x.com/radcliffeCARDIO </video> <video> Managing Patients at Transient Risk of SCD Early After Acute MI Description: In this short video, conducted at ESC EHRA 2024 in Berlin, Prof Lucas Boersma (Amsterdam UMC, NL) discusses the underestimation of risks for patients discharged from care, emphasising the role of wearable defibrillators (WCDs) as a bridge to permanent solutions like ICDs, heart transplants, or assist devices. WCDs are recommended for patients with ICD indications when implantation is delayed, those with explanted ICDs, or reversible risks of sudden cardiac death. They are also suitable for patients with reduced ejection fractions after infarction, awaiting revascularisation, or on transplant or LVAD waiting lists. An Italian study highlights clinical scenarios where WCDs provide temporary protection until definitive treatment decisions are made. To view the complete symposium, please click here: https://www.radcliffecardiology.com/video-index/managing-patients-transient-risk-scd-early-after-acute-mi-boersma This video is sponsored by Zoll. This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook: https://www.facebook.com/RadcliffeCardiology Follow us on X: https://x.com/radcliffeCARDIO </video> <video> AHA 24: ALPACAR: Phase 2 Trial of Zerlasiran in High Risk Patients Description: Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD). Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571). ALPACAR is a phase 2, randomized, five-arm, placebo-controlled trial investigating the use of zerlasiran (SLN360), a double-stranded small interfering ribonucleic acid (siRNA), in adults with elevated lipoprotein(a) at high risk of ASCVD events. 180 patients were enrolled in the trial and were followed-up at 36, 48 and 60 weeks. The primary outcome measure was time averaged change in lipoprotein(a) from baseline. Interview Questions: 1. What is the importance behind the ALPACAR trial? 2. Could you tell us about the mechanism of action behind zerlasiran? 3. What were the key findings? 4. What further research is needed in this area, and what are the next steps? Recorded on-site at AHA Conference in Chicago, 2024. Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook: https://www.facebook.com/RadcliffeCardiology Follow us on X: https://x.com/radcliffeCARDIO </video> <video> View from the Thoraxcenter: AHA 24 Wrap-Up Description: Keep up to date with the top trials from AHA 24! CLEAR-SYNERGY SELECT-CABG SUMMIT YELLOW III International Aortic Stenosis Registry AMPLATZER IDE VALOR HCM Watch our full AHA 24 coverage in our Late-Breaking and Featured Science Collection. Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook: https://www.facebook.com/RadcliffeCardiology Follow us on X: https://x.com/radcliffeCARDIO </video> <video> AHA 24: BROOKLYN: Safety and Efficacy of Obicetrapib in Patients with HeFH Description: BROOKLYN: Safety and efficacy outcomes of obicetrapib (NewAmsterdam Pharma) alongside lipid-lowering therapy in Heterozygous Familial Hypercholesterolemia (HeFH) management. Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from BROOKLYN (NCT05425745). BROOKLYN is a phase 3, randomized, placebo-controlled trial investigating the use of obicetrapib in patients with HeFH who have undergone at least eight weeks of maximally tolerated lipid modifying therapy prior to screening. 354 patients were enrolled in the trial and were followed-up after the 365-day treatment period. The primary outcome measure was the percent change from baseline to day 84 in low density lipoprotein-cholesterol. Interview Questions: 1. What is the reasoning behind the trial and the current unmet needs in HeFH management? 2. Could you tell us about the mechanism of action behind obicetrapib? 3. What was the study design and patient population? 4. What were the key findings? 5. What further research is needed in this area? Recorded on-site at AHA Conference in Chicago, 2024. Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook: https://www.facebook.com/RadcliffeCardiology Follow us on X: https://x.com/radcliffeCARDIO </video> <video> Implementing AI Algorithms in Emergency Departments: RAPIDxAI with Dr Derek Chew Description: Host, Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, Newport Beach, CA, US) is joined by PI, Dr Derek Chew (Monash Heart and Victorian Heart Institute, AU) to discuss the findings from the RAPIDxAI trial, which aims to improve the assessment of suspected cardiac chest pain in emergency departments (ED) using a machine-learning algorithm that will interpret high-sensitivity troponin test results, assisting the diagnosis of myocardial infarction (MI) and other myocardial injuries. Conducted across 12 hospitals with 9600 patients, RAPIDxAI compares AI-supported decision-making to standard of care. Investigators found that the availability of AI-based decision making tools guiding diagnostic and prognostic evaluation of high-sensitivity troponin T did not impact clinical care to improve cardiovascular outcomes. There was no increased risk using the algorithms observed in the trial, demonstrating the safety of the algorithm. Dr Itchhaporia and Dr Chew discuss the trust levels of cardiologists in implementing AI algorithms into clinical practice, and cost-effective methods of validating AI, as well as the lessons learnt from the trial. If you have any questions or suggestions for topics to cover on the Radcliffe Podcast, please email managingeditor@ecrjournal.com. Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook: https://www.facebook.com/RadcliffeCardiology Follow us on X: https://x.com/radcliffeCARDIO </video> <video> AHA 24: 3 Trials That Will Change My Practice with Dr Michelle Kittleson Description: AHA Conference 2024 - In this highlights video from AHA 2024, Dr Michelle Kittleson (Cedars-Sinai California Heart Center, US) offers a concise and insightful summary of the most influential late-breaking trials presented at the conference. Dr Kittleson discusses the pivotal studies poised to impact clinical practice and enhance patient outcomes in heart failure care. Trials covered in detail include: SUMMIT (0:32 - 4:08) SARAH (4:08 - 6:39) REALIZE-K (6:39 - 9:54) Recorded remotely from California, 2024. Support: This is an independent interview produced by Radcliffe Cardiology. Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook: https://www.facebook.com/RadcliffeCardiology Follow us on X: https://x.com/radcliffeCARDIO </video> <video> Parallax | Ep 124: Coronary Interventions and Evolving Technologies: The Year 2024 In Review Description: In this week's Parallax, Dr Ankur Kalra welcomes back Dr Sukhjinder Nijjer for their much-anticipated annual review of advancements in cardiovascular medicine that defined the year 2024. Dr Nijjer, a Consultant Cardiologist in the UK, serves as the President of the Royal Society of Medicine and is an Honorary Senior Clinical Lecturer at Imperial College London. This episode focuses on recent developments in interventional cardiology, covering coronary interventions, new device technologies and challenging patient populations. Drs Kalra and Nijjer share their perspectives and experiences, offering valuable insights, practical tips and considerations when interpreting this year’s most impactful trials: REDUCE-AMI PREVENT FAVOR III ORBITA-COSMIC DANGer SHOCK SENIOR-RITA NOTION 3 What are the most impactful cardiovascular trials of 2024? How do Dr Kalra and Dr Nijjer integrate the latest information into their daily practices? Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook: https://www.facebook.com/RadcliffeCardiology Follow us on X: https://x.com/radcliffeCARDIO </video> <video> AHA 24: KRAKEN: Phase 2 Trial of Muvalaplin in High Risk Patients Description: Safety and efficacy outcomes of muvalaplin (Eli Lilly and Company) in adults with elevated lipoprotein(a) at high risk for cardiovascular events. Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from KRAKEN (NCT05563246). KRAKEN is a phase 2, randomized, placebo-controlled trial investigating the use of an oral, daily dose of LY3473329 in adults aged 40 or over with elevated lipoprotein(a) at high risk for cardiovascular events. 233 patients were enrolled in the trial and were followed up at baseline and week 12. The primary outcome measure was the percent change from baseline in lipoprotein(a). Interview Questions: 1. What is the importance behind the KRAKEN trial? 2. Could you tell us about the mechanism of action behind muvalaplin? 3. What was the study design and patient population? 4. What were the key findings? 5. Were there any surprising or unexpected results? 6. What further research is needed in this area, and what are the next steps? Recorded on-site at AHA Conference in Chicago, 2024. Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook: https://www.facebook.com/RadcliffeCardiology Follow us on X: https://x.com/radcliffeCARDIO </video> <video> Biological Aging, AI & the Brain-Heart Connection: A Conversation with Dr Valentin Fuster Description: In this exclusive episode of the "Innovations in Cardiology" podcast series, host Dr Dipti Itchhaporia, past president of the American College of Cardiology, delves into the latest advancements in cardiovascular health. She is joined by Dr Valentin Fuster, a pioneer in the field, who shares invaluable insights into the impact of biological ageing, the connection between the heart and brain, and the role of artificial intelligence in healthcare. Dr Fuster challenges the traditional focus on chronological age, highlighting the significance of biological age as a more accurate predictor of cardiovascular risk. Together, he and Dr Itchhaporia explore innovative ways to measure biological age and discuss the factors that influence it. The conversation then shifts to the importance of early intervention in cardiovascular disease, with Dr Fuster advocating for screening in younger individuals. They also discuss the transformative potential of polypills in preventing and treating heart disease, weighing the benefits against challenges such as adherence and cost-effectiveness. As the episode wraps up, Dr Fuster offers his predictions for the future of cardiovascular care and shares valuable advice for those just beginning their careers in the field. If you have any questions or suggestions for topics to cover on the Radcliffe Podcast, please email managingeditor@ecrjournal.com Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook: https://www.facebook.com/RadcliffeCardiology Follow us on X: https://x.com/radcliffeCARDIO </video>

Contacts and Links

Description

We put great communication at the heart of better healthcare.

Radcliffe equips healthcare professionals with the skills and practical insights they need to do their best for patients, by bringing the world’s cardiovascular, renal and metabolic (CVRM) knowledge to life. We combine scientific rigour with communications expertise and technical mastery, to make knowledge-sharing as effortless and effective as possible.

We believe great communication is at the heart of great healthcare. Powerful research and ingenious innovation have always fuelled progress in health but it’s the way that new ideas are shared that ensures positive change happens quickly and equitably. For us, this is always a blend of the medium and the message – where, when and how important knowledge is communicated.

Content intended for healthcare professionals only.

Videos from channel